Literature DB >> 11999583

Progressive multifocal leukoencephalopathy in chronic lymphocytic leukemia after treatment with fludarabine.

Maria Saumoy1, Gerard Castells, Lourdes Escoda, Rafel Marés, Cristobal Richart, Aranzazu Ugarriza.   

Abstract

A 65-year-old man with chronic lymphocytic leukemia (CLL) diagnosed 11 years ago and treated with standard dose of fludarabine developed a rapidly fatal progressive neurological syndrome. Differential diagnoses included brain infiltration by CLL as opposed to progressive multifocal leukoencephalopathy (PML). A magnetic resonance imaging (MRI) scan showed a hyperintense T2-weighted signal in the left frontal region. Cerebro-spinal fluid polymerase chain reaction (PCR) was positive for virus JC (JCV). These findings were compatible with the diagnosis of PML. Fludarabine has been used to treat acute leukemias, CLL and follicular lymphomas. Its toxicity includes myelosuppression, immunosuppression and sporadic life-threatening neurotoxicity, although standard doses of it are considered safe. Late-onset fatal cerebral dysfunction caused by JCV after standard-dose fludarabine has been described previously. The widespread and increasing use of fludarabine makes it interesting to define the potential of standard doses of fludarabine for causing severe neurological side-effects such as PML.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11999583     DOI: 10.1080/10428190290006297

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  10 in total

Review 1.  CT and MR imaging of central nervous system effects of therapy in patients treated for hematological malignancies.

Authors:  Ali Guermazi; Yves Miaux; François Lafitte; Jean Ralph Zahar; Eliane Gluckman
Journal:  Eur Radiol       Date:  2003-12       Impact factor: 5.315

2.  A risk classification for immunosuppressive treatment-associated progressive multifocal leukoencephalopathy.

Authors:  Salim Chahin; Joseph R Berger
Journal:  J Neurovirol       Date:  2014-11-18       Impact factor: 2.643

Review 3.  Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps.

Authors:  Fariha Zaheer; Joseph R Berger
Journal:  Ther Adv Drug Saf       Date:  2012-10

Review 4.  The double-edged sword: Neurotoxicity of chemotherapy.

Authors:  Rajiv S Magge; Lisa M DeAngelis
Journal:  Blood Rev       Date:  2014-09-28       Impact factor: 8.250

Review 5.  Molecular regulation of JC virus tropism: insights into potential therapeutic targets for progressive multifocal leukoencephalopathy.

Authors:  Leslie J Marshall; Eugene O Major
Journal:  J Neuroimmune Pharmacol       Date:  2010-04-17       Impact factor: 4.147

Review 6.  Infection risk in patients on multiple sclerosis therapeutics.

Authors:  Eric M Williamson; Joseph R Berger
Journal:  CNS Drugs       Date:  2015-03       Impact factor: 5.749

7.  High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation.

Authors:  J R Long-Boyle; K G Green; C G Brunstein; Q Cao; J Rogosheske; D J Weisdorf; J S Miller; J E Wagner; P B McGlave; P A Jacobson
Journal:  Bone Marrow Transplant       Date:  2010-04-12       Impact factor: 5.483

8.  Severe fludarabine neurotoxicity after reduced intensity conditioning regimen to allogeneic hematopoietic stem cell transplantation: a case report.

Authors:  Claudio Annaloro; Antonella Costa; Nicola S Fracchiolla; Gabriella Mometto; Silvia Artuso; Giorgia Saporiti; Elena Tagliaferri; Federica Grifoni; Francesco Onida; Agostino Cortelezzi
Journal:  Clin Case Rep       Date:  2015-06-11

9.  Drug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases.

Authors:  Roderick P P W M Maas; Annemarie H G Muller-Hansma; Rianne A J Esselink; Jean-Luc Murk; Clemens Warnke; Joep Killestein; Mike P Wattjes
Journal:  J Neurol       Date:  2016-07-11       Impact factor: 4.849

Review 10.  A Review of Acute and Long-Term Neurological Complications Following Haematopoietic Stem Cell Transplant for Paediatric Acute Lymphoblastic Leukaemia.

Authors:  Melissa Gabriel; Bianca A W Hoeben; Hilde Hylland Uhlving; Olga Zajac-Spychala; Anita Lawitschka; Dorine Bresters; Marianne Ifversen
Journal:  Front Pediatr       Date:  2021-12-23       Impact factor: 3.418

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.